TransCode Therapeutics’ (RNAZ) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ) in a research note published on Thursday,Benzinga reports. HC Wainwright currently has a $20.00 price objective on the stock.

TransCode Therapeutics Stock Up 4.8 %

Shares of RNAZ stock opened at $0.78 on Thursday. TransCode Therapeutics has a fifty-two week low of $0.65 and a fifty-two week high of $66.33. The stock’s fifty day moving average price is $5.54 and its two-hundred day moving average price is $237.18.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.